Abstract: A method for determining a piston position of a piston in a hydraulic cylinder drive includes (i) providing a dynamic model of the cylinder drive, (ii) controlling driving of the cylinder drive with a control signal, (iii) detecting a real piston position of the piston, and (iv) adjusting parameters of the model on the basis of the real piston position. The model maps components of the cylinder drive and outputs a calculated piston position of the piston on the basis of detected operating parameters of the cylinder drive. A method of operating an arrangement having a corresponding hydraulic cylinder drive and a mechanism for implementing the methods are also disclosed herein.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: It is provided a vibration damper system for a steering wheel arrangement of a motor vehicle, which is provided for arrangement on a steering wheel element of the steering wheel arrangement. The vibration damper system comprises a vibration damping mass for damping the vibration of the steering wheel arrangement, an elastic bearing element which comprises a fastening element for fastening the elastic bearing element to one of bearing element and vibration damping mass, and a fastening means for fastening to the other of steering wheel element and vibration damping mass, wherein the elastic bearing element sectionally rests against the fastening means.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, wherein the IL-22 protein comprises at least one amino acid substitution, and their use in therapy.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty monoacid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

Abstract: The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.

Abstract: It is provided a vibration damper system for a steering wheel arrangement of a motor vehicle, which is provided for arrangement on a steering wheel element of the steering wheel arrangement. The vibration damper system comprises a vibration damping mass for damping the vibration of the steering wheel arrangement, an elastic bearing element which comprises a fastening element for fastening the elastic bearing element to one of bearing element and vibration damping mass, and a fastening means for fastening to the other of steering wheel element and vibration damping mass, wherein the elastic bearing element sectionally rests against the fastening means.

Abstract: The invention relates to MIC-1 compounds for use in the prevention and/or treatment of obesity, wherein the MIC-1 compounds is administered simultaneously, separately or sequentially with a GLP-1 compound.

Abstract: The present invention relates to the newly identified MIC-1 binding receptor, GFRAL. In vitro bioassays, for testing affinity and potency of GFRAL ligand, such as MIC- or MIC-1 variants, are provided.

Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

Abstract: The invention relates to MIC-1 compounds for use in the prevention and/or treatment of obesity, wherein the MIC-1 compounds is administered simultaneously, separately or sequentially with a GLP-1 compound.

Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

Abstract: The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.